Neurocrine Biosciences Inc. (NBIX)
$163.88
$-3.47
(-2.07%)
As on 05-Jun-2026 16:00EDT
Market cap
$16,478 Mln
Revenue (TTM)
$3,102 Mln
P/E Ratio
25.2
P/B Ratio
4.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
14.3 %
-
Industry P/E
--
-
EV/EBITDA
18.8
-
Debt to Equity
0
-
Book Value
$33.9
-
EPS
$6.5
-
Face value
--
-
Shares outstanding
100,549,983
10 Years Aggregate
CFO
$1,182.07 Mln
EBITDA
$1,030.77 Mln
Net Profit
$526.11 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences (NBIX)
| 15.5 | 22.2 | 22.8 | 31.6 | 21.1 | 11.7 | 12.7 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P 100
| 5.5 | 2.6 | 8.6 | 24.9 | 22.1 | 13.7 | 14.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences (NBIX)
| 3.9 | 3.6 | 10.3 | 40.2 | -11.1 | -10.8 | 50.5 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences (NBIX)
|
163.9 | 16,478.1 | 3,102.4 | 668.6 | 27.4 | 20.9 | 25.2 | 4.8 |
| 303.1 | 40,461.0 | 4,286.9 | 577.2 | 9.8 | 88.2 | 76.3 | 37.6 | |
| 94.2 | 20,422.4 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 29.0 | |
| 74.5 | 12,308.8 | 1,057.9 | -326.6 | -16.4 | -58.9 | -- | 25.0 | |
| 183.5 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 | |
| 47.4 | 18,823.5 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.5 | |
| 635.5 | 66,620.0 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 14.8 | 11,463.9 | 0.0 | -872.2 | -- | -287.7 | -- | 21.0 | |
| 549.9 | 23,340.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.3 | 4.0 | |
| 446.8 | 113,407.9 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout Neurocrine Biosciences (NBIX)
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive... dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. Read more
-
CEO & Director
Dr. Kevin C. Gorman Ph.D.
-
CEO & Director
Mr. Kyle W. Gano Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Neurocrine Biosciences (NBIX)
What is the current share price of Neurocrine Biosciences Inc (NBIX) Today?
The share price of Neurocrine Biosciences Inc (NBIX) is $163.88 (NASDAQ) as of 05-Jun-2026 16:00 EDT. Neurocrine Biosciences Inc (NBIX) has given a return of 21.08% in the last 3 years.
What is the current PB & PE ratio of Neurocrine Biosciences Inc (NBIX)?
The P/E ratio of Neurocrine Biosciences Inc (NBIX) is 25.17 times as on 05-Jun-2026.
The P/B ratio of Neurocrine Biosciences Inc (NBIX) is 4.84 times as on 05-Jun-2026, a 9 premium to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
30.38
|
4.47
|
|
2024
|
41.15
|
5.42
|
|
2023
|
53.98
|
6.04
|
|
2022
|
77.93
|
7.05
|
|
2021
|
90.21
|
5.88
|
What is the 52 Week High and Low of Neurocrine Biosciences Inc (NBIX)?
The 52-week high and low of Neurocrine Biosciences Inc (NBIX) are Rs 169.57 and Rs 122.14 as of 07-Jun-2026.
What is the market cap of Neurocrine Biosciences Inc (NBIX)?
Neurocrine Biosciences Inc (NBIX) has a market capitalisation of $ 16,478 Mln as on 05-Jun-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Neurocrine Biosciences Inc (NBIX)?
Before investing in Neurocrine Biosciences Inc (NBIX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.